M-A: The role of SGLT2 inhibitors in heart failure.

The Role of SGLT2 Inhibitors in Heart Failure: A Systematic Review and Meta-Analysis – Cardiology Research and Practice

Related:

ESC Position Paper: Cardiac, renal, and metabolic effects of SGLT2 inhibitors.

Guideline: SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes – This guidance recommends a risk-based approach, advising against starting SGLT-2 inhibitors or GLP-1 receptor agonists in patients with three or fewer cardiovascular risk factors and without established CVD or CKD.

Summary: SGLT2 inhibitors and GLP-1 receptor agonists established and emerging indications.

M-A: SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure.

Meta-analysis: Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with Type 2 diabetes

#ESCCongress – [Abstract Only] SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: A meta-analysis of the EMPEROR-Reduced and DAPA-HF trials

[Abstract Only] Randomized Trial: SGLT2 Inhibitor Improves Outcomes in Patients with Heart Failure Even in the Absence of Diabetes